Avita Medical touts pivotal trial of ReCell burn injury device

Avita Medical (ASX:AVH) said today that a pivotal trial of its ReCell autologous cell harvesting device met its co-primary endpoints.

The device, designed to help heal deep, full-thickness burns, demonstrated a statistically significant reduction in donor skin requirements compared to the standard of care and achieved comparable wound closure, Avita touted.

Get the full story at our sister site, Drug Delivery Business News.

The post Avita Medical touts pivotal trial of ReCell burn injury device appeared first on MassDevice.

from MassDevice https://ift.tt/2qCbk9H